Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.

Melanoma Clinical Trial

Official title:

A Phase I/Ib, Open-label, Multi-center, Study of DKY709 as a Single Agent and in Combination With PDR001 in Patients With Advanced Solid Tumors

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03891953
• Other study ID #: CDKY709A12101C
• Secondary ID: 2018-002580-26
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: May 7, 2019
• Est. completion date: September 12, 2024

Study information

• Verified date: April 2024
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase I/Ib, open label study. The escalation portion will characterize the safety and tolerability of DKY709 and DKY709 in combination with PDR001 in subjects with NSCLC or melanoma who have received prior anti-PD-1/PD-L1 therapy, or subjects with NPC. After the determination of the MTD/RD for a particular treatment arm, dose expansion will further assess safety, tolerability, PK/PD, and anti-tumor activity of each regimen at the MTD/RD.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 98
• Est. completion date: September 12, 2024
• Est. primary completion date: September 12, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Signed informed consent must be obtained prior to participation in the study.

2. Patients must be =18 years of age at the time of informed consent form (ICF) signature.

3. Patients with advanced/metastatic cancer who have progressed despite having received standard therapy in the metastatic setting or are intolerant to standard therapy, and for whom no effective standard therapy is available

4. In expansion: patient with measurable disease as determined by RECIST version 1.1,

5. Dose escalation, patients must fit into one of the following groups:

• NSCLC, previously treated with an anti-PD-1/PD-L1 therapy

• Cutaneous Melanoma, previously treated with an anti-PD-1/PD-L1 therapy

• NPC

Dose expansion part, patients must fit into one of the following groups:

• NSCLC with historic documentation of PD-L1 = 1%. Patients must have progressive disease after having experienced at least 4 months of investigator-assessed disease stability or response on prior anti-PD-L1-containing therapy

• Cutaneous Melanoma, previously treated with anit-PD-1/PD-L1 therapy. Patients should have documented progression following anti-PD-1/PD-L1 therapy.

• NPC, naive to anti-PD-1/PD-L1 therapy

• mssCRC, naive to anti-PD-1/PD-L1 therapy

• TNBC, naive to anti-PD-1/PD-L1 therapy

6. ECOG Performance Status = 1

7. Patients must have a site of disease amenable to core needle biopsy, and be a candidate for tumor biopsy according to the treating institution's guidelines. Patients must be willing to undergo a new tumor biopsy at baseline, and during therapy on the study. Exceptions may be considered after documented discussion with Novartis.

Exclusion Criteria:

1. Presence of symptomatic central nervous system (CNS) metastases, or CNS metastases that require local CNS-directed therapy (such as radiotherapy or surgery), or increasing doses of corticosteroids within 2 weeks prior to study entry. Patients with treated brain metastases should be neurologically stable for at least 4 weeks prior to study entry and off steroids for at least 2 weeks before administration of any study treatment.

2. History of severe hypersensitivity reactions to any ingredient of study drug(s) or other mAbs and/or their excipients.

3. Patient with out of range laboratory values defined as:

• Creatinine clearance (calculated using Cockcroft-Gault formula, or measured) < 40 mL/min

• Total bilirubin > 1.5 x ULN, except for patients with Gilbert's syndrome who are excluded if total bilirubin > 3.0 x ULN or direct bilirubin > 1.5 x ULN

• Alanine aminotransferase (ALT) > 3 x ULN, except for patients that have tumor involvement of the liver, who are excluded if ALT > 5 x ULN

• Aspartate aminotransferase (AST) > 3 x ULN, except for patients that have tumor involvement of the liver, who are excluded if AST > 5 x ULN

• Absolute neutrophil count (ANC) < 1.0 x 109/L

• Platelet count < 75 x 109/L (growth factor or transfusion support may not be used to meet entry criterion)

• Hemoglobin (Hgb) < 8 g/dL (growth factor or transfusion support may not be used to meet entry criterion)

• Magnesium, calcium or phosphate abnormality CTCAE > grade 1

• Potassium abnormality CTCAE = grade 1; supplementation to meet eligibility criteria is acceptable

4. Clinically significant cardiac disease or impaired cardiac function, including any of the following:

• Clinically significant and/or uncontrolled heart disease such as congestive heart failure requiring treatment (NYHA grade = 2), uncontrolled hypertension or clinically significant arrhythmia

• On screening: QTcF > 450 msec (male), or > 460 msec (female)

• QTc not assessable

• Congenital long QT syndrome

• History of familial long QT syndrome or known family history of as Torsades de Pointes

• Acute myocardial infarction or unstable angina pectoris < 3 months prior to study entry

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Non-Small-Cell Lung
• Colorectal Neoplasms
• Melanoma
• Microsatellite Stable Colorectal Cancer
• Nasopharyngeal Carcinoma
• Triple Negative Breast Cancer
• Triple Negative Breast Neoplasms

Intervention

Drug:
• DKY709
Novel immunomodulatory agent
• PDR001
PDR001 is a high-affinity, ligand-blocking, humanized IgG4 monoclonal antibody directed against PD-1 that blocks the binding of PD-L1 and PD-L2

Locations

Country	Name	City	State
Germany	Novartis Investigative Site	Dresden
Germany	Novartis Investigative Site	Essen
Hong Kong	Novartis Investigative Site	Shatin New Territories
Japan	Novartis Investigative Site	Chuo ku	Tokyo
Spain	Novartis Investigative Site	Barcelona	Catalunya
Taiwan	Novartis Investigative Site	Taipei
United States	Dana Farber Cancer Institute	Boston	Massachusetts
United States	Massachusetts General Hospital Massachusetts Gen Hosp	Boston	Massachusetts
United States	Sarah Cannon Research Institute Drug Ship - 3	Nashville	Tennessee

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

United States,  Germany,  Hong Kong,  Japan,  Spain,  Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety of DKY709 single agent treatment or DKY709 in combination with PDR001.	Incidence and severity of AEs and SAEs	24 months
Primary	incidence of Dose Limiting Toxicities (DLTs)	The incidence of DLTs during the first cycle of treatment with single agent DKY709 or the combination of DKY709 with PDR001.	1 Month
Primary	Tolerability of DKY709 single agent treatment or DKY709 in combination with PDR001.	Incidence and severity of AEs and SAEs	24 months
Secondary	AUC of DKY709 and PDR001	AUC	24 months
Secondary	Cmax of DKY709 and PDR001	Cmax	24 months
Secondary	Tmax of DKY709 and PDR001	Tmax	24 months
Secondary	Half-life of DKY709 and PDR001	Half-life	24 months
Secondary	Progression Free Survival (PFS)	Determine PFS in each part of the study	24 months
Secondary	Best Overall Response (BOR)	Determine BOR in each part of the study	24 months
Secondary	Duration of Response (DOR)	Determine DOR in each part of the study	24 months
Secondary	Time to Progression (TTP)	Determine TTP in each part of the study	24 months